Background: Colorectal cancer (CRC) is the third most common cancer diagnosis in the Western world.
| INTRODUC TI ON
Colorectal cancer (CRC) is the third most common cancer diagnosis and a major cause of mortality in the Western World. 1-3 CRC usually develops from focal changes within benign polyps via a multistep process involving a series of genetic, histological and morphological changes that accumulate over time. 4 This dwell time allows for early detection and removal of precursor lesions to prevent development of CRC. Moreover, detection of early-stage CRC improves survival rates which is why screening programs for CRC are increasingly adapted worldwide. 5, 6 Nowadays, several CRC screening modalities are available, and each test has its own performance characteristics and acceptability profile. Preferably, a screening test should be affordable, non-invasive and precise to achieve a high rate of cooperation from asymptomatic individuals. Faecal immunochemical testing (FIT) is currently the most commonly used non-invasive screening test for CRC. This stool-based test is relatively cheap and easy to perform, but population screening with FIT results in missed cancers and unnecessary colonoscopy procedures due to suboptimal sensitivity and specificity of 56%-89% and 92%-97% respectively, for detection of CRC. [7] [8] [9] Furthermore, ideally a screening test should detect treatable precursor lesions to prevent development of cancer, but sensitivity of FIT for advanced adenomas (AAs) is low, only 39%-57%. 7, 8 These suboptimal test characteristics of FIT and sometimes disappointing adherence rates to FIT screening programs (37%-62%) illustrate the need for a new, more accurate, non-invasive diagnostic test for CRC and its precursor lesions. [10] [11] [12] [13] Analysis of volatile organic compounds (VOCs) might be a promising new technique for early detection and surveillance of various diseases, including CRC. VOCs are gaseous carbon-based end products of physiologic and pathologic metabolic processes which can be detected in all biological specimens (eg breath, saliva, urine, faeces, blood). 14, 15 It has been shown that VOC concentration profiles and/or VOC composition differ between patients with and without certain diseases, ranging from infectious diseases 16, 17 to malignancies. [18] [19] [20] Some potential CRC-associated VOCs have already been identified in small pilot studies, [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] but the VOCs identified differed among studies and (external) validation of the results is lacking. Data on VOC's associated with colorectal polyps is even more scarce. 25, 29, 32, 33 Thus far, most studies that evaluated the potential of VOCs to serve as a non-invasive biomarker for CRC used faecal samples and gas chromatography-mass spectrometry (GC-MS) for VOC analysis.
We hypothesised that breath analysis with electronic nose (e-nose) technology may be more suitable for clinical practice since breath sampling may be more acceptable for (asymptomatic) individuals. In addition, contrary to GC-MS, e-nose technology is relatively lowcost, easily operated and it allows for point-of-care diagnosis.
Therefore, the objective of this study was to evaluate if exhaled VOCs can serve as a non-invasive biomarker for CRC and its precursor lesions using e-nose technology. In this study, breath analysis was performed with Aeonose devices (The eNose Company). This specific type of e-nose allows for datasets of multiple devices to be combined which facilitates the generation of large data sets to develop disease models. Furthermore, once-developed models can be transferred to new e-noses which will further aid in clinical implementation of e-nose technology. 36 
| MATERIAL S AND ME THODS

| Protocol and registration
The study protocol was approved by the ethics committee of Enschede, the Netherlands, and thereafter by the local ethics committees of the participating centres. This study was performed in compliance with the Declaration of Helsinki and registered at https ://clini caltr ials.gov (Identifier NCT03488537). All study patients provided written informed consent before breath testing.
| Study design and population
This cross-sectional, proof-of-principle study was conducted in two secondary care hospitals in the Netherlands (Medisch Spectrum Twente, Enschede and Bernhoven, Uden). All adult patients referred for elective colonoscopy were invited for study participation.
Patients with known inflammatory bowel disease (IBD) or (previous) malignancy were excluded (not including basal cell carcinoma or squamous cell carcinomas of the skin) from breath testing.
| Breath test
All members of the research team attended a training session for study instructions and e-nose training before the start of the study.
Patients were invited for breath testing during a pre-colonoscopy consultation and/or on the day of the examination just before the colonoscopy procedure. Some patients performed two breath tests; one before and one after bowel preparation to evaluate the influence of bowel preparation on VOC profiles. Baseline characteristics were collected from all eligible patients by research nurses using standardised forms for patient interviews and by evaluation of their medical records.
Five e-noses were used for breath testing and all tests were performed in the same room at each hospital location ( Figure 1 ).
Patients were instructed to breathe into an e-nose for five consecutive minutes using a disposable mouthpiece while wearing a nose clip. Failed breath tests were excluded from analysis and the reason for exclusion was documented by the research nurse.
| Aeonose
In this study, breath analysis was performed with Aeonose devices (The eNose Company), which are portable, battery-powered devices, that contain three metal-oxide sensors (AMS AG) with different material properties. VOCs present in exhaled breath cause redox-reactions at the sensor surfaces of the e-nose which results in conductivity changes that are measured and analysed. VOCs interact competitively with these sensors, depending on the physical and chemical characteristics of the sensor material. As the reaction kinetics are temperature-dependent, the metal-oxide sensors of the device are guided through a sinusoidal temperature profile to optimise the amount of information gathered from exhaled breath.
Basically, in this way a virtual sensor array is built mimicking identical sensors at different temperatures. 37 During each cycle, conductivity is measured 32 times. In the end, all conductivity values are combined to represent the composition of the total VOC mixture, called a "breathprint", and each breathprint consists of approximately 7000 conductivity values.
Breath analysis with this e-nose takes 15 minutes in which the patient breathes into the device for 5 minutes. Inhaled air is filtered by two carbon filters to minimise contamination of the measurements by environmental VOCs and the mouthpiece has a High Efficiency Particulate Air filter (HEPA; 3M) that prevents contamination of the e-nose by bacteria or viruses.
| Endoscopic evaluation (reference test)
Patients received bowel preparation prior to colonoscopy. The bowel preparation prescribed was left to the discretion of the treating physician. Colonoscopy data and histopathology reports were evaluated for the presence and size of colorectal lesions. Patients were categorised into one of the following subgroups; controls (patients without any colonic neoplasia or other abnormality), hyperplastic polyps (HPs), non-NAs, AAs (polyps ≥10 mm, >25% villous pathology or high-grade dysplasia) or CRC. If multiple neoplastic lesions were present, classification was based on the most advanced lesion found. All diagnoses were double checked by two members of the research team.
Patients with an incomplete colonoscopy procedure, poor bowel preparation (Boston Bowel Preparation Score [BBPS] <6) or new diagnosis of colitis were excluded from analysis.
| Blinding
Patients, endoscopists and pathologists remained blinded for the outcome of the breath test throughout the study.
| Study outcomes
The primary outcome was the ability of the e-nose to distinguish patients with CRC from controls based on VOC patterns. Secondary outcomes included the ability of the e-nose to distinguish patients with precursor lesions (AAs, NAs, HPs) from CRC and controls. In addition, the effect of bowel preparation on VOC patterns was explored.
| Power calculation
The nature of the statistical method used in e-nose technology makes an exact sample size calculation impossible. Previous studies conducted with this specific e-nose technology have suggested that at least 25 cases and 25 control patients are required to build a disease-specific model. [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] For this study, we therefore aimed to include at least 60 patients with CRC; 40 CRC patients to develop a disease-specific model and 20 to validate the diagnostic accuracy of the algorithms. 
| Statistical analysis
| Baseline characteristics
| VOC analysis
Machine Learning was applied to distinguish between breath profiles of controls and patients with (pre-)cancerous lesions. During each breath measurement 64 × 36 × 3 data points were recorded.
Strict temperature controls of the sensors limits variability between sensors of different devices. 36 Potential small differences are tackled by pre-treatment of the data including standardisation. 48 After pre-processing, data were compressed using a Tucker3-like solution which resulted in a single vector of limited size per participant. 49 Together with the disease diagnosis, the vector was used to train an artificial neural network. Using the data analysis package Aethena (The eNose Company) several permutations of data pre-processing, sensor combinations, vector lengths and network topologies were investigated to optimise results. More details on the data analysis have been published elsewhere. 48
| Primary outcome
Breath sample analysis was performed in three phases for CRC versus controls. Only breath tests conducted before bowel preparation were used for these analyses.
• Phase 1: Training models: Development of disease-specific training models.
An important aspect of e-nose technology is that the artificial neural network used to analyse breath tests first needs to be trained to recognise disease-specific mixtures of VOCs. Two-thirds of the breath tests were used to develop "training models" which were validated in the remaining data (phase II). Breath samples were randomly assigned to either the "training" or "validation" phase.
The artificial neural network was trained using the "leave-10%out" cross validation technique to verify that training was successfully applied at the disease classification, and not on some artefact. Another important aspect of e-nose technology is that the diagnostic accuracy of an artificial neural network generally improves when more data become available for training until a certain level of stability is reached. Therefore, after the validation phase, all data was made available to further train the artificial neural network using the "leave-10%-out" cross validation technique.
| Secondary outcomes
The three phases described above were also followed to develop algorithms to differentiate between AAs and controls. For all other secondary outcomes only final disease models were developed (phase III) because we only aimed to explore if VOC analysis could be used to differentiate between these subgroups. Again, only breath tests conducted before bowel preparation were used for model development except for the analyses in which the influence of bowel preparation was evaluated. Table 1 . All groups showed a male sex predominance and controls were slightly younger (P < 0.05) than patients with neoplastic lesions. 
| RE SULTS
| Baseline characteristics
| CRC versus controls
| AAs versus controls
The training model for AAs had an AUC of 0.71 with a sensitivity of 82% and a specificity of 59%. Accuracy of this model was slightly lower in the validation group, AUC of 0.61. The final model for AAs versus control had an AUC of 0.73, with a sensitivity of 79% and a specificity of 59% (Table 2 ). Baseline characteristics of the development group and validation group did not differ significantly (data not shown).
| Correctly versus incorrectly predicted patients
Baseline characteristics such as age, gender, body mass index (BMI), co-morbidities, fasting meal and use of antibiotics or proton pomp inhibitors (PPI) were not significantly different between correctly and incorrectly predicted patients (Table 3 ). In addition, time of measurement did not significantly influence accuracy of the blind predictions. CRC predictions were slightly better in the first half (P = 0.38) while predictions of AAs were more accurate in the second half (P = 0.10). Control patients with a history of polypectomy (n = 10) were misclassified as AA in 20% (false positives, P = 0.32).
| Secondary outcomes
All final disease models for secondary outcomes (except for AAs versus controls) are shown in Table 4 . The e-nose was able to differentiate between CRC and NAs with an AUC of 0.85, but was unable to differentiate between CRC and AAs. The e-nose was also able to distinguish patients with CRC and AAs from controls (AUC of 0.72), but VOC profiles of AAs and NAs were too similar. In addition, the e-nose was unable to distinguish patients with adenomatous polyps (NA + AA) from controls.
With regards to bowel preparation; 207 patients performed a breath test before and after bowel preparation. Four patients diagnosed with AAs failed their second breath tests. These patients were therefore excluded from this specific analysis. The e-nose was able to differentiate between all patients before and after bowel preparation, AUC of 0.72. Analysis of breath tests before and after bowel preparation within subgroups yielded an AUC of 0.82 for controls and 0.70 for AAs. Only 19 CRC patients performed a breath test before and after bowel preparation which was too little for analysis.
| D ISCUSS I ON
This multicentre study suggests that breath analysis with e-nose technology could become a promising, non-invasive, diagnostic tool for the detection of CRC. The e-nose technology used in this study was able to differentiate between VOC profiles of patients with CRC and patients with normal colonoscopy with an AUC of 0.84 which indicates that exhaled VOC profiles differ between these patients and that these differences can be captured with an e-nose. Furthermore, the results of this study also suggest that patients with AA have a distinct VOC profile.
In the last decade, multiple proof-of-principle studies have demonstrated the efficacy of utilising VOC profiles for clinical diagnostics. VOC analysis has not only been used successfully for the detection of several types of cancers such as lung, 18, 19 breast, 20, 50 prostate, 51, 52 gastric and oesophageal cancer, 53, 54 but also for the detection of various endoluminal gastrointestinal diseases like IBD, 55, 56 Helicobacter pylori in the stomach 57 and coeliac disease. 58 Furthermore, some studies have also suggested that VOC analysis can be used to differentiate between various diseases. 18, 23, 34, 39, 59 Although the findings of these studies still need to be validated in larger studies, the results seem to support the hypothesis that pathological processes in the body have the potential to influence VOC profiles and that each disease has its own specific VOC signature. [18] [19] [20] 23, 34, 39, [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] The exact mechanism behind the generation of disease-specific VOCs is complex. With regard to CRC-related VOCs it is thought that uncontrolled cell growth at the tumour site and systemic responses associated with carcinogenesis (ie increased catabolism, increased oxidative stress and immune activation) contribute to the observed changes in VOC profiles. 60, 61 In addition, there is also growing evidence linking the gut microbiome to CRC development through interactions with the host's immune system, production of cancer-associated metabolites and release of genotoxic virulence factors. 62 It is therefore plausible that changes in VOC profiles of CRC patients are, at least in part, the result of changes in the gut microbiome. Furthermore, concomitant disease, diet-, lifestyle-and medication-related factors also have the potential to influence VOC profiles, which is why it will take some time before the mechanisms behind the generation of CRC-associated VOCs will be clarified. [63] [64] [65] [66] Meanwhile, the evidence of potential VOCs that might serve as biomarkers for CRC is accumulating. Several proof-of-principle studies have already reported significant differences in VOCs between CRC patients and controls using various biological specimens for VOC analysis ie breath, [21] [22] [23] [24] faeces, 25-30 urine 31-35 and blood. 22 These pilot studies reported an AUC for CRC ranging between 0.67 and 0.98, with a sensitivity and specificity ranging between 63%-100% and 58%-94% respectively, similar to our study.
Unfortunately, it is not possible to compare the results of these studies because some studies used a chemical analytical technique with the aim to detect the occurrence, identity and changes in quantities of VOCs, while other studies used sensor arrays with pattern recognition technologies with the aim to detect collective differences in the chemical composition of all VOCs. Furthermore, the lack of standardised methods for all phases of VOC analysis further complicates comparison of study data even among studies that used the same technique for VOC analysis. Nevertheless, the results of these pilot studies suggest that CRC has a specific VOC signature which can be detected in various biological specimens. [21] [22] [23] [24] [25] [26] [27] [28] [29] [31] [32] [33] [34] [35] 67 Hitherto, five studies have evaluated the potential of exhaled VOCs to serve as a non-invasive biomarker for CRC. [21] [22] [23] [24] 68 GC-MS was used in two studies, 21, 22 one study used an e-nose 68 and two studies evaluated both techniques 23, 24 for VOC analysis. All four GC-MS studies were able to identify a pattern of discriminatory VOCs, consisting of 4-15 VOCs. No single discriminatory VOC could be identified which likely reflects the complexity of the metabolic derangements and systemic responses associated with CRC. [21] [22] [23] [24] 68 Interestingly, the VOCs identified differed among studies, which may be explained by a combination of differences in patient characteristics, breath sampling methods, storage conditions, GC-MS devices and statistical methods used among these studies. Studies that evaluated the use of a cross-reactive nanosensor reported an AUC of 0.38-0.91 for CRC. 23, 24, 68 Only Altomore and colleagues 68 were unable to detect a significant differences between the exhaled VOC profiles of patients with CRC and controls, AUC of 0.38.
Sensors used in their PEN3 e-nose may have been less sensitive to CRC-associated VOCs than sensors used in the other two studies, and our study. 23, 24 Our study also evaluated the ability of VOCs to serve as biomarkers for precursor lesions of CRC, since cost-efficacy of screening would be able to accurately detect these lesions to prevent the development of CRC. The e-nose used in this study was able to detect AAs with an AUC of 0.73, which is in line with the study of de Meij et al, 29 who reported an AUC of 0.79 for the detection of AAs using faecal samples. Three other studies were unable to differentiate between patients with AAs and controls using faecal 25 is reassuring that fasting did not seem to influence the accuracy of the disease models (P = 0.45 for CRC and P = 0.84 for AA-model) since this will make the implementation of breath analysis in clinical practice easier.
This study has several strengths. All consecutive adult colonoscopy patients were invited for study participation in two different Some limitations of our study should also be indicated. Most importantly, the number of failed breath tests, almost 10%, raises concern regarding the feasibility of the breath sampling technique used.
However, our breathing protocol may have been too strict since other studies using the same e-nose did not report such high failure rates, [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [70] [71] [72] neither in children with severe asthma or cystic fibrosis (<2%), 72 nor in adult patients with acute exacerbation of chronic obstructive pulmonary disease (0%). 71 In this study, two-thirds of the failed tests were suboptimal tests; ie interrupted tests by talking, laughing, coughing or inappropriate enclosement of the mouthpiece.
In clinical practice these suboptimal tests can be repeated immediately (this was not allowed in our study) and additional training of research nurses may further reduce the number of failed tests.
Nonetheless, the results of this study do underline the importance of an objective tool to evaluate the quality of breath samples before clinical implementation of breath analysis is considered. Another limitation of our study was the use of an imperfect reference test, up to 25% of all polyps are still missed with conventional colonoscopy, which may have led to misclassification of patients limiting the discriminatory power of the developed algorithms. 73 In addition, this study did not collect information on medication use, but only evaluated the presence of co-morbidities between patient groups.
Other study limitations are inherent to e-nose technology such as potential reproducibility issues, sensor drift, instrument variability and loss of sensitivity in the presence of alcohol which need to be addressed in further studies. 74 Nevertheless, in this study five different e-noses were used and accuracy of the training models did not In conclusion, this multicentre study suggests that breath analysis using e-nose technology has the potential to serve as an easyto-use, non-invasive diagnostic tool for the detection of CRC and its precursor lesions.
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